Alamar Biosciences Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
222
- Stock Symbol
-
ALMR
- Investments
-
1
- Share Price
-
$30.87
- (As of Friday Closing)
Alamar Biosciences General Information
Description
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Contact Information
Website
www.alamarbio.comCorporate Office
- 47071 Bayside Parkway
- Fremont, CA 94538
- United States
Corporate Office
- 47071 Bayside Parkway
- Fremont, CA 94538
- United States
Alamar Biosciences Timeline
Alamar Biosciences Stock Performance
As of 13-Nov-2026, Alamar Biosciences’s stock price is $30.87. Its current market cap is $2.14B with 69.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $30.87 | $31.76 | $18.84 - $39.61 | $2.14B | 69.5M | 601K | -$1.13 |
Alamar Biosciences Financials Summary
As of 30-Sep-2026, Alamar Biosciences has a trailing 12-month revenue of $114M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|
| EV | 2,165,566 | ||
| Revenue | 114,052 | 74,211 | 25,142 |
| EBITDA | (53,608) | (27,049) | (46,463) |
| Net Income | (55,002) | (29,819) | (47,073) |
| Total Assets | 378,027 | 139,992 | 149,511 |
| Total Debt | 42,350 | 41,473 | 33,101 |
Alamar Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alamar Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Alamar Biosciences Comparisons
Industry
Financing
Details
Alamar Biosciences Competitors (3)
One of Alamar Biosciences’s 3 competitors is SomaLogic Operating Company, a Formerly PE-Backed company based in Boulder, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SomaLogic Operating Company | Formerly PE-Backed | Boulder, CO | ||||
| Quanterix | Formerly PE-Backed | Billerica, MA | ||||
| Olink Proteomics | Formerly PE-Backed | Uppsala, Sweden |
Alamar Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
News about Alamar Biosciences
Dive into recent articles by PitchBook offering invaluable insights and context.
Alamar Biosciences Patents
Alamar Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222207-A1 | Novel multiplex nulisa-based assay to detect multiple forms of phosphorylated brain-derived tau and total tau in blood | Pending | 16-Apr-2025 | ||
| WO-2026187693-A1 | Compositions, methods and kits for improved biomolecule conjugation | Pending | 03-Mar-2025 | ||
| EP-4812598-A1 | Molecular barcode set and use thereof in multiplex proximity detection assays | Pending | 20-Nov-2023 | ||
| WO-2025111396-A1 | Molecular barcode set and use thereof in multiplex proximity detection assays | Inactive | 20-Nov-2023 | ||
| EP-4812597-A1 | Reduction of non-cognate signal in multiplex proximity ligation assays | Pending | 20-Nov-2023 | C12Q1/6804 |
Alamar Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alamar Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alamar Biosciences Investments (1)
Alamar Biosciences’s most recent deal was a Spin-Off with Attovia Therapeutics. The deal was made on 01-Jan-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Attovia Therapeutics | 01-Jan-2023 | Spin-Off | Drug Discovery |
Alamar Biosciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Alamar Biosciences FAQs
-
When was Alamar Biosciences founded?
Alamar Biosciences was founded in 2018.
-
Where is Alamar Biosciences headquartered?
Alamar Biosciences is headquartered in Fremont, CA.
-
What is the size of Alamar Biosciences?
Alamar Biosciences has 222 total employees.
-
What industry is Alamar Biosciences in?
Alamar Biosciences’s primary industry is Diagnostic Equipment.
-
Is Alamar Biosciences a private or public company?
Alamar Biosciences is a Public company.
-
What is Alamar Biosciences’s stock symbol?
The ticker symbol for Alamar Biosciences is ALMR.
-
What is the current stock price of Alamar Biosciences?
As of 13-Nov-2026 the stock price of Alamar Biosciences is $30.87.
-
What is the current market cap of Alamar Biosciences?
The current market capitalization of Alamar Biosciences is $2.14B.
-
What is Alamar Biosciences’s current revenue?
The trailing twelve month revenue for Alamar Biosciences is $114M.
-
Who are Alamar Biosciences’s competitors?
SomaLogic Operating Company, Quanterix, and Olink Proteomics are competitors of Alamar Biosciences.
-
What is Alamar Biosciences’s annual earnings per share (EPS)?
Alamar Biosciences’s EPS for 12 months was -$1.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
